These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 30755279

  • 1. Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.
    Heeren AM, Rotman J, Stam AGM, Pocorni N, Gassama AA, Samuels S, Bleeker MCG, Mom CH, Zijlmans HJMAA, Kenter GG, Jordanova ES, de Gruijl TD.
    J Immunother Cancer; 2019 Feb 12; 7(1):43. PubMed ID: 30755279
    [Abstract] [Full Text] [Related]

  • 2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 3. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer.
    Heeren AM, Koster BD, Samuels S, Ferns DM, Chondronasiou D, Kenter GG, Jordanova ES, de Gruijl TD.
    Cancer Immunol Res; 2015 Jan 01; 3(1):48-58. PubMed ID: 25361854
    [Abstract] [Full Text] [Related]

  • 4. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
    Zehbe I, Kaufmann AM, Schmidt M, Hohn H, Maeurer MJ.
    J Immunother; 2007 Jan 01; 30(5):523-32. PubMed ID: 17589293
    [Abstract] [Full Text] [Related]

  • 5. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
    Zhang F, Bai H, Gao R, Fei K, Duan J, Zhang Z, Wang J, Hu X.
    Cancer Immunol Immunother; 2020 Dec 01; 69(12):2599-2611. PubMed ID: 32591861
    [Abstract] [Full Text] [Related]

  • 6. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
    Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F, Miura Y, Hashimoto K, Murayama Y, Kaira K, Kobayashi K.
    Cancer Immunol Res; 2020 Mar 01; 8(3):334-344. PubMed ID: 31871122
    [Abstract] [Full Text] [Related]

  • 7. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients.
    Fattorossi A, Battaglia A, Ferrandina G, Buzzonetti A, Legge F, Salutari V, Scambia G.
    Gynecol Oncol; 2004 Jan 01; 92(1):106-15. PubMed ID: 14751146
    [Abstract] [Full Text] [Related]

  • 8. Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth.
    Heeren AM, Rotman J, Samuels S, Zijlmans HJMAA, Fons G, van de Vijver KK, Bleeker MCG, Kenter GG, Jordanova EJ, de Gruijl TD.
    J Immunother Cancer; 2021 Oct 01; 9(10):. PubMed ID: 34697217
    [Abstract] [Full Text] [Related]

  • 9. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
    Hladíková K, Partlová S, Koucký V, Bouček J, Fonteneau JF, Zábrodský M, Tachezy R, Grega M, Špíšek R, Fialová A.
    Oral Oncol; 2018 Jul 01; 82():75-82. PubMed ID: 29909905
    [Abstract] [Full Text] [Related]

  • 10. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer.
    Battaglia A, Buzzonetti A, Martinelli E, Fanelli M, Petrillo M, Ferrandina G, Scambia G, Fattorossi A.
    Int J Radiat Oncol Biol Phys; 2010 Apr 01; 76(5):1546-53. PubMed ID: 20338481
    [Abstract] [Full Text] [Related]

  • 11. Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.
    van Poelgeest MI, Visconti VV, Aghai Z, van Ham VJ, Heusinkveld M, Zandvliet ML, Valentijn AR, Goedemans R, van der Minne CE, Verdegaal EM, Trimbos JB, van der Burg SH, Welters MJ.
    Cancer Immunol Immunother; 2016 Dec 01; 65(12):1451-1463. PubMed ID: 27619514
    [Abstract] [Full Text] [Related]

  • 12. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S, Tan M, Li YD, Cheng MA, Farmer E, Ferrall L, Gaillard S, Roden RBS, Hung CF, Wu TC.
    Cancer Immunol Immunother; 2021 Apr 01; 70(4):1049-1062. PubMed ID: 33108473
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
    Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML.
    Clin Cancer Res; 2019 Jan 01; 25(1):110-124. PubMed ID: 30242022
    [Abstract] [Full Text] [Related]

  • 14. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area.
    Heeren AM, de Boer E, Bleeker MC, Musters RJ, Buist MR, Kenter GG, de Gruijl TD, Jordanova ES.
    Oncotarget; 2015 Oct 20; 6(32):32484-93. PubMed ID: 26431490
    [Abstract] [Full Text] [Related]

  • 15. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL.
    J Thorac Oncol; 2018 Apr 20; 13(4):521-532. PubMed ID: 29269008
    [Abstract] [Full Text] [Related]

  • 16. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes.
    Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, Xiong D, Liu Q, Tian Y, Lin H, Guo J, Wen S, Dong W, Yang X, Yuan Y, Yue Z, Lei S, Wu Q, Ran L, Xie L, Wang Y, Gao L, Tian Q, Zhou X, Sun B, Xu L, Tang Z, Ye L.
    Cell; 2022 Oct 27; 185(22):4049-4066.e25. PubMed ID: 36208623
    [Abstract] [Full Text] [Related]

  • 17. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M.
    J Immunother Cancer; 2016 Oct 27; 4():68. PubMed ID: 27777777
    [Abstract] [Full Text] [Related]

  • 18. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX, Chen BG, Plautz GE.
    J Immunol; 2002 Sep 15; 169(6):3314-20. PubMed ID: 12218152
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.